Precigen Reports Third-Quarter 2026 Results
Precigen reported third-quarter 2026 results, highlighting sequential PAPZIMEOS revenue growth and positive cash flow ahead of guidance.
Story updates
09:06:32 PM UTC
SquawkNews
Precigen 3Q Rev $74.1M >PGEN
09:06:55 PM UTC
SquawkNews
Precigen reported Q3 2026 PAPZIMEOS revenue of $72.9M, up 37% quarter over quarter; total revenue was $74.1M. Net income was $35.8M, or $0.08 per diluted share, and operating cash flow was $11.9M; prior-year comparisons were affected by one-time items.Material DetailsContext by AI AnalystThis is an…
09:09:58 PM UTC
SquawkNews
PAPZIMEOS® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 b
GERMANTOWN, Md., Nov. 4, 2026 // -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced third quarter 2026 financial results and business updates."Pr…